195 related articles for article (PubMed ID: 2113823)
1. 5-Hydroxytryptamine and arachidonic acid metabolites modulate extensive platelet activation induced by collagen in cats in vivo.
De Clerck F; Loots W; Somers Y; Beetens J; Wouters L; Wynants J; Janssen PA
Br J Pharmacol; 1990 Apr; 99(4):631-6. PubMed ID: 2113823
[TBL] [Abstract][Full Text] [Related]
2. Interplay between platelet-derived 5-hydroxytryptamine and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet-rich coronary thrombosis.
Vandeplassche G; Hermans C; Van Dael L; Wouters L; De Clerck F
J Cardiovasc Pharmacol; 1993 Jan; 21(1):56-69. PubMed ID: 7678680
[TBL] [Abstract][Full Text] [Related]
3. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
4. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
de Chaffoy de Courcelles D; De Clerck F
Eur J Pharmacol; 1990 Mar; 188(2-3):161-9. PubMed ID: 2318257
[TBL] [Abstract][Full Text] [Related]
5. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
[TBL] [Abstract][Full Text] [Related]
6. 5-Hydroxytryptamine dominates over thromboxane A2 in reducing collateral blood flow by activated platelets.
Loots W; De Clerck F
Am J Physiol; 1993 Jul; 265(1 Pt 2):H158-64. PubMed ID: 8342629
[TBL] [Abstract][Full Text] [Related]
7. Arachidonic acid metabolites, ADP and thrombin modulate occlusive thrombus formation over extensive arterial injury in the rat.
De Clerck F; Van Gorp L; Beetens J; Verheyen A; Janssen PA
Blood Coagul Fibrinolysis; 1990 Aug; 1(3):247-58. PubMed ID: 2151728
[TBL] [Abstract][Full Text] [Related]
8. R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin.
Hoet B; Falcon C; De Reys S; Arnout J; Deckmyn H; Vermylen J
Blood; 1990 Feb; 75(3):646-53. PubMed ID: 2153424
[TBL] [Abstract][Full Text] [Related]
9. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
[TBL] [Abstract][Full Text] [Related]
10. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
Vandeplassche G; Hemans C; Van de Water A; Xhonneux R; Wouters L; Van Ammel K; De Clerck F
Circ Res; 1991 Aug; 69(2):313-24. PubMed ID: 1830517
[TBL] [Abstract][Full Text] [Related]
12. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
[TBL] [Abstract][Full Text] [Related]
13. Effect of ridogrel on vascular contractions caused by vasoactive substances released during platelet activation.
Janssens WJ; Cools FJ; Hoskens LA; Van Nueten JM
Thromb Haemost; 1990 Aug; 64(1):91-6. PubMed ID: 2148850
[TBL] [Abstract][Full Text] [Related]
14. The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication.
De Cree J; Geukens H; Gutwirth P; De Clerck F; Vercammen E; Verhaegen H
Int Angiol; 1993 Mar; 12(1):59-68. PubMed ID: 8376914
[TBL] [Abstract][Full Text] [Related]
15. Involvement of platelet-derived 5-hydroxytryptamine in thromboxane A2-induced aggregation in cat platelets.
Ogawa T; Sugidachi A; Asai F; Koike H
Blood Coagul Fibrinolysis; 1998 Apr; 9(3):233-40. PubMed ID: 9663705
[TBL] [Abstract][Full Text] [Related]
16. Amplification mechanisms in platelet activation and arterial thrombosis.
De Clerck FF; Janssen PA
J Hypertens Suppl; 1990 Dec; 8(7):S87-93. PubMed ID: 2128890
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of thromboxane A2 synthesis and thromboxane A2/prostaglandin endoperoxide receptors by ridogrel: anti-thrombotic effect in vivo in rat mesenteric arteries.
Bourgain RH; Andries R; Decuyper K; De Clerck F
J Lipid Mediat; 1991; 3(1):3-11. PubMed ID: 1837488
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
19. Thromboxane A2/prostaglandin endoperoxide (TXA2/PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor--TXA2/PG-END receptor antagonist.
Heylen L; De Clerck F; Somers Y; Leysen JE
Blood Coagul Fibrinolysis; 1991 Oct; 2(5):617-21. PubMed ID: 1838285
[TBL] [Abstract][Full Text] [Related]
20. The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects.
Naran NH; Chetty N
Thromb Res; 1997 Dec; 88(5):399-407. PubMed ID: 9556227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
